-+ 0.00%
-+ 0.00%
-+ 0.00%

Precision BioSciences presents preclinical PBGENE-DMD data ahead of Phase 1/2 FUNCTION-DMD trial

PUBT·04/28/2026 11:12:33
Listen to the news
Precision BioSciences presents preclinical PBGENE-DMD data ahead of Phase 1/2 FUNCTION-DMD trial
  • Precision BioSciences flagged new preclinical PBGENE-DMD data for oral presentation at ASGCT 2026, scheduled for May 14, 2026.
  • Study showed gene editing treatment produced durable functional improvement in a humanized Duchenne muscular dystrophy mouse model.
  • Additional findings in early-juvenile mice supported potential benefit from earlier intervention in younger patient populations.
  • Program remains in development for Duchenne muscular dystrophy, with Phase 1/2 FUNCTION-DMD expected to enroll ambulatory patients with mutations between exons 45 and 55.
  • Regulatory positioning includes FDA Orphan Drug designation granted July 2025, Fast Track designation granted February 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604280701BIZWIRE_USPR_____20260428_BW083428) on April 28, 2026, and is solely responsible for the information contained therein.